Why the study?
Does early initiation of gemfibrozil reduce long-term CHD mortality in dyslipidemic middle-aged men?
Population
4,081 dyslipidemic middle-aged men in a primary prevention setting
Comparison
Gemfibrozil vs Placebo
Design
Cohort, double-blind, placebo-controlled (during the initial 5-year trial)
Follow-up
18 years
Authors
Loading...
Early gemfibrozil was associated with lower 18-year CHD mortality; hypothesis-generating for legacy effects, should not yet alter practice.
Does early initiation of gemfibrozil reduce long-term CHD mortality in dyslipidemic middle-aged men?
Early initiation of gemfibrozil in dyslipidemic men provides a sustained long-term reduction in CHD mortality, particularly in those with features of metabolic syndrome, despite subsequent treatment crossover.
Tenkanen et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: